Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY027 for Early Treatment of COVID-19
NCT04649515Phase 3Terminated
- Sponsor
- Tychan
- Start
- Dec 2020
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of TY027 in coronavirus disease 2019 (COVID-19), sponsored by Tychan. Started Dec 2020; status: terminated.
02
Drugs
TY027
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04649515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649515.